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Purpose: Viruses are a common cause of exacerbations in chronic obstructive pulmonary disease 
(COPD). They activate toll-like receptors (TLRs) 3, 7, and 8, leading to a pro-inflammatory 
response. We have characterized the responses of TLR3 and TLR7/8 in lung tissue explants 
from COPD patients and control smokers.
Methods: We prepared lung whole tissue explants (WTEs) from patients undergoing surgery 
for confirmed or suspected lung cancer. In order to mimic the conditions of viral infection, we 
used poly(I:C) for TLR3 stimulation and R848 for TLR7/8 stimulation. These TLR ligands 
were used alone and in combination. The effects of tumor necrosis factor α (TNFα) neutral-
ization and dexamethasone on TLR responses were examined. Inflammatory cytokine release 
was measured by enzyme-linked immunosorbent assay and gene expression by quantitative 
real-time polymerase chain reaction.
Results: WTEs from COPD patients released higher levels of pro-inflammatory cytokines 
compared with WTEs from smokers. Activation of multiple TLRs led to a greater than addi-
tive release of TNFα and CCL5. TNFα neutralization and dexamethasone treatment decreased 
cytokine release.
Conclusion: This WTE model shows an enhanced response of COPD compared with controls, 
suggesting an increased response to viral infection. There was amplification of innate immune 
responses with multiple TLR stimulation.
Keywords: COPD, poly(I:C), R848, cytokines, lung explant
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by poorly reversible 
airflow limitation and airway inflammation that arise in response to the inhalation 
of noxious particles. COPD patients can suffer with exacerbations; these events are 
an acute increase in symptoms beyond normal day-to-day variation. The majority of 
exacerbations are due to viral or bacterial respiratory infections and result in increased 
levels of airway and systemic inflammation. COPD exacerbations are often treated 
with high doses of anti-inflammatory corticosteroids.1
Viruses such as rhinovirus, adenovirus, and influenza cause COPD exacerbations.2 
The viral genome is recognized by pattern recognition receptors, including toll-like 
receptors (TLRs) such as TLR3, TLR7, and TLR8, that are expressed on the cell 
surface and in the endosomes of immune and structural cells. Stimulation of these 
TLRs activates transcription factors, such as nuclear factor-κB and interferon (IFN) 
regulatory factors, which cause increased secretion of pro-inflammatory cytokines and 
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chemokines (such as tumor necrosis factor α [TNFα] and 
CCL5) as well as an antiviral response with increased secre-
tion of type I and III IFNs.3
The effects of TLR activation have traditionally been 
studied using synthetic ligands of these receptors, such as 
poly(I:C) that targets TLR3, using single-cell culture systems. 
However, whole tissue explants (WTEs) offer the opportunity 
to investigate TLR-induced responses in a complex system 
with multiple cell types. Previous studies have demonstrated 
that COPD lung tissue readily responds to TLR3 and TLR4 
stimulation.4,5 Viruses can activate multiple TLRs; for 
example, rhinovirus is recognized by both TLR3 and TLR7.6,7 
Previous studies using COPD lung tissue have not assessed 
simultaneous stimulation of multiple TLRs.
In this study, we characterized the response of lung WTE 
of COPD patients to TLR3 and TLR7/8 ligands, poly(I:C), 
and R848, respectively, as a model of viral infection. The 
primary aim was to compare the inflammatory response of 
samples from COPD patients with those from controls and to 
investigate the effect of simultaneous stimulation with TLR3 
and TLR7/8 on the inflammatory response. The secondary 
aim was to investigate the effect of TNFα inhibition and 
corticosteroids on these TLR-induced responses.
Materials and methods
Patient information
Lung samples were obtained from 52 patients undergoing 
surgery for confirmed or suspected lung cancer. All the patients 
were current or ex-smokers; the complete demographic details 
are presented in Table 1. COPD patients (n=33) were diag-
nosed according to the Global Initiative for Chronic Obstruc-
tive Lung Disease guidelines1 and had forced expiratory 
volume in 1 second  % predicted ,80% and ratio of forced 
expiratory volume in 1 second  to forced vital capacity ,70%. 
Patients without COPD were classified as smokers with normal 
lung function (n=19). Ex-smokers were defined as individu-
als who had not smoked for at least 1 year. All the patients 
gave written informed consent, and the study was approved 
by the local research ethics committee (03/SM/396, NRES 
Committee North West – Greater Manchester South). The 
demographics of patient samples used in various experiments 
are summarized in Tables S1 and S2.
Preparation of whole tissue explants
Human lung tissue was prepared as previously described.4 
Tissue that was distal from the tumor was used. Briefly, 
using two sterile scalpels, 1–5 g of tissue was cut into small 
(~1 mm3) fragments – WTEs. WTEs were rinsed with RPMI-
1640 medium (Sigma-Aldrich, Dorset, UK) supplemented 
with 10% (v/v) fetal bovine serum (Invitrogen, Paisley, UK), 
100 U penicillin/0.1 mg streptomycin (Sigma-Aldrich), and 
2 mM l-glutamine (Invitrogen). WTEs (30±3 mg) were placed 
in 24-well plates with 800 μL supplemented RPMI medium 
per well and incubated at 37°C, 5% (v/v) CO
2
 overnight.
Tissue stimulation with Tlr ligands
TLR3 (poly(I:C)) and TLR7/8 ligand (R848) stock solutions 
(Invivogen, San Diego, CA, USA) were diluted in supple-
mented RPMI-1640 medium to obtain final concentrations 
ranging from 0.01 to 1,000 μg/mL, depending on the experi-
ment. Following overnight incubation of WTE, the medium 
was replaced with 800 μL of fresh supplemented RPMI 
medium, containing medium only, poly(I:C) only, R848 only, 
or poly(I:C) and R848 combined. Plates were then incubated 
at 37°C, 5% (v/v) CO
2
 for 1, 6, 24, or 48 hours. Supernatants 
were collected at a set time point and stored at -20°C, and 
tissue was stored in RNAlater (Invitrogen) at -80°C. All the 
conditions were performed in triplicate.
TnFα neutralization
Human TNFα Antibody (Clone #28401) and Mouse IgG
1
 
Isotype (Clone #11711) were purchased from R&D Systems 
Europe (Abingdon, UK), and the stock solutions were pre-
pared according to the manufacturers’ instructions. Following 
overnight incubation of WTE, the medium was replaced with 
784 μL of fresh supplemented RPMI medium, containing 
medium only, neutralizing TNFα antibody only (1 μg/mL), 
or control immunoglobulin G (IgG) antibody only (1 μg/mL). 
Plates were then incubated at 37°C, 5% (v/v) CO
2
 for 1 hour. 
Then, 16 μL of medium only, poly(I:C) only, or R848 only 
was added to the wells, and the plates were incubated for 
further 24 hours. Supernatants were collected and stored 
at -20°C, and tissue was stored in RNAlater (Invitrogen) 
at -80°C. All the conditions were performed in triplicate.
Table 1 Demographics of patients used in this study
COPD (n=33) Smokers (n=19)
sex (M/F) 17/16 7/12
Age, years 68.7±7.9 63.7±8.9
FeV1 1.84±0.60 2.53±0.61
FeV1 % predicted 73.4±17.5 99.3±20.0
FeV1/FVC % ratio 59.6±11.1 75.1±0.1
smoking status (current/ex) 21/12 7/12
Smoking history (pack-years) 42 (13–126) 37 (2–71)
ICS use? (yes/no) 8/25 0/19
gOlD stage (I/II/III/IV) 10/20/3/0 na
Note: Data are presented as mean ± standard deviation or mean (range).
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; ICS, inhaled corticosteroid; M, male; F, female; ex, ex-smoker; GOLD, 
Global Initiative for Chronic Obstructive Lung Disease; COPD, chronic obstructive 
pulmonary disease; NA, not applicable.
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effect of dexamethasone
Dexamethasone was diluted in dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich) to stock concentration of 10 mM. Following 
overnight incubation of WTE, the medium was replaced with 
784 μL of fresh supplemented RPMI medium, containing 
DMSO only (controls) or dexamethasone only (final concen-
tration 1 μM). Plates were then incubated at 37°C, 5% (v/v) 
CO
2
 for 1 hour. Then, 16 μL of supplemented RPMI medium 
containing poly(I:C) only, R848 only, or poly(I:C) and R848 
was added to the wells, and the plates were incubated for fur-
ther 24 hours. Supernatants were collected and stored at -20°C 
and tissue was stored in RNAlater (Invitrogen) at -80°C. All 
the conditions were performed in triplicate. Final DMSO 
concentration present in all conditions was 0.01% (v/v).
Enzyme-linked immunosorbent assay
TNFα, CCL5, and IL-6 protein levels in supernatants were 
measured by enzyme-linked immunosorbent assay (ELISA; 
R&D Systems Europe, Abingdon, UK) according to the 
manufacturer’s protocol. All data were adjusted for tissue 
weight and were presented as pg/mL/mg of tissue.
Quantitative real-time polymerase chain 
reaction
The levels of TNFα, CCL5, and IL-6 mRNA following 
TLR stimulation were measured using Taqman polymerase 
chain reaction (PCR) (see Supplementary materials for the 
detailed method).
statistics
All the data were analyzed and plotted in GraphPad Prism 5 
(GraphPad Software, Inc., San Diego, CA, USA). Normality 
was assessed using the Kolmogorov–Smirnov test. All TNFα 
and IL-6 ELISA data presented were parametric, whereas 
CCL5 ELISA data and PCR data were nonparametric. In the 
time course experiments, cytokine release or relative gene 
expression in response to a TLR ligand was compared with 
time-matched unstimulated controls using paired t-tests (or 
Wilcoxon signed-rank test for nonparametric data). In the 
experiments with different concentrations of TLR ligand, 
cytokine release was analyzed by one-way analysis of vari-
ance (ANOVA) with Dunnett’s posttest. CCL5 was analyzed 
using Friedman test with Dunn’s posttest. Cytokine levels 
after simultaneous TLR3 and TLR7/8 stimulation were com-
pared with the cytokine levels using a single TLR agonist 
using paired t-tests or Wilcoxon signed-rank test for CCL5. 
The combination effect was also compared with the predicted 
sum (where absolute levels of cytokines released by single 
ligands were added together) using paired t-tests or Wilcoxon 
signed-rank test. The effects of TNFα neutralization were 
analyzed using multiple repeated ANOVA with Dunnett’s 
posttest and Friedman with Dunn’s posttest for nonparametric 
data. The effect of dexamethasone on cytokine release was 
compared with time-matched control using paired t-tests (or 
Wilcoxon signed-rank test for CCL5 data).
Results
Time course of poly(I:C)- and 
R848-induced cytokine release and 
mrna expression
Initial experiments were performed to establish the time 
course of poly(I:C)- and R848-induced inflammatory 
response in WTE from COPD patients (n=7) and smokers 
(n=6). It was decided a priori to pool the data from both the 
groups for the primary aim of characterizing the time course of 
cytokine release (Figure 1) and mRNA production (Figure 2). 
Poly(I:C) (100 μg/mL) and R848 (10 μg/mL) caused time-
dependent increases in TNFα, CCL5, and IL-6 release. In 
general, cytokine secretion was relatively low at 1 and 6 hours 
with higher levels at 24 and 48 hours; the only exception was 
high levels of TNFα release at 6 hours after R848 stimulation. 
Poly(I:C) induced higher levels of CCL5 and IL-6 compared 
with R848 reaching statistical significance at 24 and 48 hours, 
respectively. However, R848 was much more potent at TNFα 
induction throughout the time course (Figure S1 shows a 
direct comparison of R848 and poly(I:C)). On the basis of 
these results, the time point of 24 hours for maximal cytokine 
release was used for the subsequent experiments.
Changes in cytokine release were preceded or correlated 
with changes at the mRNA level. Thus, both poly(I:C) and 
R848 significantly upregulated cytokine mRNA expression 
from 6 to 48 hours after stimulation for all cytokines that were 
analyzed (Figure 2). There was some evidence of increased 
mRNA expression at 1 hour, most notably for TNFα after 
R848 stimulation. Poly(I:C) caused significantly lower TNFα 
and higher CCL5 mRNA expression than R848 (Figure S2).
Because of the limited sample size, we were unable to 
observe any consistent differences between COPD patients 
(n=7) and smokers (n=6) for cytokine release (Figure S3) 
and mRNA production (Figure S4).
Poly(I:C) and R848 stimulation: 
comparison of COPD patients and 
smokers
The response of WTE from COPD patients (n=13) and smokers 
(n=13) was compared. Cytokine secretion was TLR ligand con-
centration-dependent with maximal effects at 100–1,000 μg/mL 
of poly(I:C) and 1–10 μg/mL of R848 (Figure 3). There was 
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evidence across the concentration response curve of signifi-
cantly increased CCL5 release from COPD patients compared 
with smokers after both poly(I:C) and R848 stimula tion. There 
was a similar pattern for TNFα secretion, although significant 
differences were observed at lower concentrations of TLR 
ligands. There were no differences for IL-6 release.
Current smoking caused lower TNFα release in the 
smokers group, but there was no effect in COPD patients 
(Figure S5). Current smoking had no effect on CCL5 or 
IL-6 release.
simultaneous activation of Tlr3 and 
Tlr7/8
Poly(I:C) (100 μg/mL) and R848 (10 μg/mL) when com-
bined caused TNFα and CCL5 secretion that was greater 
than when the ligand was used alone in WTE from COPD 
Figure 1 Time course of cytokine release from poly(I:C)- and R848-stimulated lung tissue.
Notes: The release of TnFα (A and D), CCL5 (B and E), and IL-6 (C and F) from poly(I:C)- (100 μg/ml) (A–C) and r848-stimulated (10 μg/ml) (D–F) whole tissue 
explants from smokers and COPD patients (pooled, n=13) were measured after 1, 6, 24, and 48 hours. Data presented as mean with SEM (TNFα and Il-6) or median with 
range (CCl5). *, **, ***Refer to significantly above time-matched unstimulated control (P,0.05, 0.01, 0.001, respectively). Results were obtained using paired t-tests (TnFα 
and Il-6) and Wilcoxon matched-pairs test (CCl5).
Abbreviations: TnFα, tumor necrosis factor α; IL-6, interleukin 6; COPD, chronic obstructive pulmonary disease; SEM, standard error of the mean; h, hour(s).
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Figure 2 Time course of cytokine mRNA expression in poly(I:C)- and R848-stimulated lung tissue.
Notes: The mrna expression of TnFα (A and D), CCL5 (B and E), and IL-6 (C and F) in poly(I:C)- (100 μg/ml) (A–C) and r848-stimulated (10 μg/ml) (D–F) whole tissue explants 
from smokers and COPD patients (pooled, n=13) was measured after 1, 6, 24, and 48 hours. Data presented as median with range. *, **, ***Refer to significantly above time-matched 
unstimulated control (P,0.05, 0.01, 0.001, respectively). Horizontal line at y=1 represents unstimulated control. results were obtained using a Wilcoxon matched-pairs test.
Abbreviations: TnFα, tumor necrosis factor α; IL-6, interleukin 6; COPD, chronic obstructive pulmonary disease; h, hour(s).
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patients (n=12) and smokers (n=10) (Figure 4). Further-
more, TNFα and CCL5 secretion was at a level that was 
greater than the sum of the levels induced by the ligands 
used alone (predicted fully additive effect). The release of 
IL-6 in response to poly(I:C) and R848 was greater than 
that when the TLR ligands were used alone but lower than 
the predicted fully additive effect induced by these ligands. 
Cytokine levels induced after the addition of poly(I:C) and 
R848 combined were similar in WTE from COPD patients 
and smokers.
TnFα amplifies subsequent TLR3- and 
TLR7/8-induced pro-inflammatory 
response
A TNFα neutralizing antibody was preincubated with COPD 
WTE (n=6). TNFα neutralization caused a significant reduc-
tion in poly(I:C)-induced CCL5 and R848-induced IL-6 
levels (Figure 5). Poly(I:C)-induced IL-6 and R848-induced 
CCL5 levels were also reduced after TNFα neutralization, 
but these changes were not statistically significant. A control 
antibody had no effect on cytokine release.
Figure 3 Concentration-dependent induction of cytokine release from poly(I:C)- and R848-stimulated lung tissue.
Notes: The release of TnFα (A and D), CCL5 (B and E), and IL-6 (C and F) from poly(I:C)- (A–C) and r848-stimulated (D–F) whole tissue explants from smokers (n=13) 
and COPD patients (n=13, poly(I:C); n=12, R848) after 24 hours. Data are presented as mean with SEM (TNFα and Il-6) or as median with range (CCl5). #, ##, ###refer to 
significantly above time-matched unstimulated control (P,0.05, 0.01, 0.001, respectively). *, **Refer to significant difference between subject groups (P,0.05, 0.01, respectively). 
Results were obtained using one way ANOVA with Dunnett’s post-test (TNFα and IL-6) and Friedman test with Dunn’s post-test (CCL5) #P,0.05 and an unpaired t-test 
(TnFα and IL-6) and Mann-Whitney U test (CCl5) *P,0.05.
Abbreviations: TnFα, tumor necrosis factor α; IgG, immunoglobulin G; IL-6, interleukin 6; COPD, chronic obstructive pulmonary disease; SEM, standard error of the mean.
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Figure 4 Effect of simultaneous activation of TLR3 and TLR7/8 on pro-inflammatory cytokine release from lung tissue.
Notes: The effect of simultaneous TLR3 and TLR7/8 activation (poly(I:C) =100 μg/mL, R848=10 μg/mL, respectively) on the release of TNFα (A), CCL5 (B), and IL-6 (C) 
from whole tissue explants from smokers (n=10) and COPD patients (n=12) after 24 hours. Data are presented as mean with seM (TnFα and Il-6) or as median with range 
(CCL5). Sum represents the predicted additive result of poly(I:C) + R848 cytokine release. *, **, ***Refer to significant difference between conditions (P,0.025, 0.005, 0.0005, 
respectively). #, ##Refer to significantly above predicted sum (P,0.05, 0.01, respectively). Results are in response to paired t-tests (TnFα and Il-6) and Wilcoxon tests (CCl5).
Abbreviations: TnFα, tumor necrosis factor α; IL-6, interleukin 6; COPD, chronic obstructive pulmonary disease; SEM, standard error of the mean; Comb, combination.
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Corticosteroid inhibition of cytokines
WTE from COPD patients (n=6) were treated with dexametha-
sone (1 μM) prior to stimulation with poly(I:C) alone, R848 
alone, or both TLR ligands simultaneously (Figure 6). Dexam-
ethasone significantly decreased cytokine release in the majority 
of conditions, ranging from 52% to 82% at 24 hours.
Discussion
We have characterized the cytokine response of COPD 
WTE to synthetic viral TLR stimuli. Poly(I:C) and R848 
both caused increased TNFα and CCL5 secretion in COPD 
patients compared with smokers. This increased inflamma-
tory response could contribute to the pathophysiology of 
COPD exacerbations after viral infection. Combination of 
these TLR ligands produced greater responses than either 
ligand alone. TNFα had an important role in promoting 
the secretion of other cytokines, and we show that these 
responses are partially inhibited by corticosteroids.
Increased cytokine secretion has been reported in COPD 
patients compared with controls using TLR4-stimulated 
Figure 5 effect of TnFα neutralization on pro-inflammatory cytokine release from lung tissue.
Notes: The effect of pre-exposure to neutralizing TnFα IgG antibody (nTNFα IgG) and control IgG antibody (Isotype IgG) (both 1 μg/ml) on CCl5 (A) and Il-6 (B) 
release from whole tissue explants from COPD patients (n=6) that were either unstimulated (control) or stimulated with poly(I:C) (100 μg/ml) or r848 (10 μg/ml) for 24 
hours. Data are presented as median with range (CCl5) or mean with seM (Il-6). *, **Refer to significantly below untreated levels (P,0.05, 0.01, respectively). Results are 
in response to one way ANOVA with Dunnett’s post-test (IL-6) and Friedman test with Dunn’s post-test (CCL5).
Abbreviations: TnFα, tumor necrosis factor α; IgG, immunoglobulin G; IL-6, interleukin 6; COPD, chronic obstructive pulmonary disease; SEM, standard error of the mean; 
ANOVA, analysis of variance.
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Figure 6 Effect of dexamethasone on pro-inflammatory cytokine release from TLR-stimulated lung tissue.
Notes: The effect of dexamethasone (1 μM) on poly(I:C)- (100 μg/mL), R848- (10 μg/mL), and combination-induced release of TNFα (A), CCL5 (B), and IL-6 (C) after 
24 hours from whole tissue explants from COPD patients (n=6). Data are presented as mean with seM (TnFα and Il-6) or median with range (CCl5). *, **, ***refer to 
significantly below DMSO control (P,0.05, 0.01, 0.001, respectively). Results are in response to paired t-tests (TnFα and Il-6) and Wilcoxon tests (CCl5).
Abbreviations: TnFα, tumor necrosis factor α; IL-6, interleukin 6; COPD, chronic obstructive pulmonary disease; SEM, standard error of the mean; Dex, dexamethasone; 
DMSO, dimethyl sulfoxide.
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WTE.4 We observed similar findings using different TLR 
ligands relevant to viral infection. Interestingly, differences 
in cytokine release between smokers and COPD patients 
were not observed when both the TLR agonists were used 
simultaneously. This might signify near maximal inflamma-
tion being achieved in this tissue model, making it difficult 
to observe differences between groups.
Viral infections are likely to trigger the activation of 
multiple pattern recognition receptors. The combination 
of poly(I:C) and R848 caused TNFα and CCL5 secretion 
that was greater than the predicted fully additive effect of 
combining the TLR ligands. This raises the possibility that 
this combination of TLR ligands caused a synergistic pro-
inflammatory effect. However, IL-6 was not released in such 
a synergistic manner. This may be due to IL-6 levels being 
already high when stimulated by one ligand. Perhaps using 
lower ligand concentrations for this experiment would reveal 
a different pattern for IL-6, and it would be important to 
perform experiments using different TLR ligand concentra-
tions in combination in order to confirm this possibility of 
synergism. Others have also examined multiple TLR acti-
vation in different models, eg, monocyte-derived dendritic 
cells and macrophages, and also have observed synergistic 
release of various cytokines (including TNFα and IL-6).8–13 
However, synergy in cytokine release was not observed in 
monocyte-derived macrophages.10
TLR3 and TLR7/8 use different molecular adaptors to 
activate downstream signaling pathways: TLR3 signals 
via TRIF, whereas TLR7 and TLR8 use MyD88.14 Previ-
ous studies examining simultaneous activation of different 
TLRs have demonstrated that activation of both MyD88- and 
TRIF-dependent pathways results in synergistic cytokine 
release.10,15 The exact mechanisms are still to be elucidated, 
but the crosstalk between multiple pro-inflammatory path-
ways downstream of TLRs appears to play a role in this 
process.10
Viral infections are a common cause of COPD exacerba-
tions and are associated with increased airway inflammation 
in COPD patients.16–18 The additive, and possibly synergistic, 
cytokine production reported here are mechanisms that 
are likely to contribute to the excessive airway inflamma-
tion during viral infections, predisposing to other harmful 
pathophysiological effects such as tissue damage. On the 
other hand, the host immune response is required for the 
recruitment of cells responsible for pathogen clearance. 
A variety of mechanism are involved in viral clearance,19 
and our investigations focus more on immune pathways that 
could cause excessive inflammation.
There is evidence of attenuation of TLR-induced cytokine 
release in cells pretreated with cigarette smoke extract or 
cells derived from smokers.20–22 For example, Metcalfe et al20 
showed that acute cigarette smoke extract exposure decreased 
TLR-induced cytokine release from alveolar macrophages 
while Chen et al22 observed attenuation in TLR2- and TLR4-
induced cytokine release from alveolar macrophages from 
smokers compared with nonsmokers. We observed that the 
TLR7/8- and TLR3-induced TNFα response was attenuated 
by current smoking in the smokers group but that there was no 
effect in COPD patients. Furthermore, there was no effect of 
current smoking on CCL5 and IL-6. One should be cautious 
when interpreting this subanalysis with small sample sizes. 
Overall, we feel that current smoking had a minimal impact 
on the data presented.
TNFα is implicated in inflammatory responses in 
COPD.23–25 Multiple cell types are able to release and respond 
to TNFα, including epithelial cells and macrophages.26–28 
We found that a neutralizing TNFα antibody attenuated 
TLR3- and TLR7/8-induced release of CCL5 and IL-6. 
Similar observations were made by Hackett et al using lung 
tissue exposed to lipopolysaccharide (LPS).4 These data sug-
gest that TNFα is required for maximal pro-inflammatory 
responses in the lung tissue. However, anti-TNFα treatment 
did not have any benefit in COPD patients.29,30 It is possible 
that TNFα plays a role as an amplifier of TLR signaling 
during infection in COPD patients, rather than having a 
significant role in the stable clinical state.
Corticosteroids are commonly used in COPD therapy, 
either as regular inhaled treatment or as short courses of 
oral treatment during exacerbations.1 We showed that 
dexamethasone partially inhibited the release of all three 
pro-inflammatory cytokines measured. Similarly, other 
in vitro studies have shown that corticosteroids partially sup-
press pro-inflammatory cytokine release from different cell 
types, including alveolar macrophages, monocyte-derived 
macrophages, and primary bronchial epithelial cells.26,31–33 
Our observations suggest a partial anti-inflammatory effect 
by corticosteroids on COPD lung tissue during viral TLR 
stimulation.
Activation of TLR7 is being investigated as a therapeutic 
option for asthma, as there is evidence that this skews the 
immune response away from a Th2 profile and toward a 
Th1 profile, which may be useful for suppressing allergic 
inflammation.34,35 Our research was not focused on this ques-
tion, but we show how TLR7 stimulation may affect COPD 
lung immune responses. It is possible that TLR antagonists 
may be beneficial in COPD patients to limit inflammation 
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associated with smoking, as various TLRs are impli cated 
in pro-inflammatory responses to cigarette smoke.36–40 
However, since TLRs play a role in infection, using TLR 
antagonists during infection could lead to increased pathogen 
proliferation.41 A balanced approach to TLR therapeutics is 
required to limit tissue-destructive inflammation without 
compromising pathogen clearance.42
There were some practical limitations to our study. The 
vast majority of patients undergoing cancer surgery were 
current or ex-smokers, so it was difficult to recruit lifelong 
nonsmokers as a control group. Additionally, it is possible 
that the presence of cancer may influence the immune 
response, even though we used tumor-free tissue.
In summary, we have demonstrated that COPD WTE 
showed a greater pro-inflammatory response to TLR3 or TLR7/8 
activation than control smokers. Interestingly, simultaneous 
stimulation of these TLRs caused innate immune responses 
that were at least additive. The model described here can be 
further used to model and dissect the COPD immune response 
during viral infection, for the purpose of identifying molecular 
pathways suitable for pharmacological intervention.
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